دورية أكاديمية
أعرض في EDS

Piperlongumine potentiates the effects of gemcitabine in in vitro and in vivo human pancreatic cancer models.

التفاصيل البيبلوغرافية
العنوان: Piperlongumine potentiates the effects of gemcitabine in in vitro and in vivo human pancreatic cancer models.
المؤلفون: Mohammad J; Department of Biological Sciences, North Dakota State University, Fargo, ND 51808, USA., Dhillon H; Department of Biological Sciences, North Dakota State University, Fargo, ND 51808, USA., Chikara S; Department of Biological Sciences, North Dakota State University, Fargo, ND 51808, USA., Mamidi S; Genome Sequencing Center, HudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA., Sreedasyam A; Genome Sequencing Center, HudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA., Chittem K; Department of Plant Pathology, North Dakota State University, Fargo, ND 51808, USA., Orr M; Department of Statistics, North Dakota State University, Fargo, ND 51808, USA., Wilkinson JC; Department of Chemistry and Biochemistry, North Dakota State University, Fargo, ND 51808, USA., Reindl KM; Department of Biological Sciences, North Dakota State University, Fargo, ND 51808, USA.
المصدر: Oncotarget [Oncotarget] 2017 Dec 23; Vol. 9 (12), pp. 10457-10469. Date of Electronic Publication: 2017 Dec 23 (Print Publication: 2018).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: eCollection Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Albany, N.Y. : Impact Journals
مستخلص: Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers due to a late diagnosis and poor response to available treatments. There is a need to identify complementary treatment strategies that will enhance the efficacy and reduce the toxicity of currently used therapeutic approaches. We investigated the ability of a known ROS inducer, piperlongumine (PL), to complement the modest anti-cancer effects of the approved chemotherapeutic agent gemcitabine (GEM) in PDAC cells in vitro and in vivo . PDAC cells treated with PL + GEM showed reduced cell viability, clonogenic survival, and growth on Matrigel compared to control and individually-treated cells. Nude mice bearing orthotopically implanted MIA PaCa-2 cells treated with both PL (5 mg/kg) and GEM (25 mg/kg) had significantly lower tumor weight and volume compared to control and single agent-treated mice. RNA sequencing (RNA-Seq) revealed that PL + GEM resulted in significant changes in p53-responsive genes that play a role in cell death, cell cycle, oxidative stress, and DNA repair pathways. Cell culture assays confirmed PL + GEM results in elevated ROS levels, arrests the cell cycle in the G0/G1 phase, and induces PDAC cell death. We propose a mechanism for the complementary anti-tumor effects of PL and GEM in PDAC cells through elevation of ROS and transcription of cell cycle arrest and cell death-associated genes. Collectively, our results suggest that PL has potential to be combined with GEM to more effectively treat PDAC.
Competing Interests: CONFLICTS OF INTEREST The authors declair no conflicts of interest.
References: Tumour Biol. 2016 Aug;37(8):10793-804. (PMID: 26874726)
Bioinformatics. 2015 Jan 15;31(2):166-9. (PMID: 25260700)
Sci Rep. 2016 May 20;6:26357. (PMID: 27198178)
Int J Oncol. 2016 Apr;48(4):1426-36. (PMID: 26848023)
J Clin Oncol. 2002 Aug 1;20(15):3270-5. (PMID: 12149301)
Anticancer Res. 2011 Nov;31(11):3747-56. (PMID: 22110196)
JAMA. 2007 Jan 17;297(3):267-77. (PMID: 17227978)
Sci Rep. 2016 Feb 17;6:21648. (PMID: 26884312)
Bioinformatics. 2011 Nov 1;27(21):2987-93. (PMID: 21903627)
N Engl J Med. 2011 May 12;364(19):1817-25. (PMID: 21561347)
Int J Cancer. 2010 Jul 15;127(2):257-68. (PMID: 19908231)
CA Cancer J Clin. 2017 Jan;67(1):7-30. (PMID: 28055103)
Braz J Med Biol Res. 2006 Jun;39(6):801-7. (PMID: 16751987)
Nat Med. 2011 Apr;17 (4):500-3. (PMID: 21460848)
N Engl J Med. 2013 Oct 31;369(18):1691-703. (PMID: 24131140)
Toxicol In Vitro. 2013 Sep;27(6):1626-33. (PMID: 23603476)
Cancer Biother Radiopharm. 2013 Apr;28(3):218-25. (PMID: 23477357)
J Clin Oncol. 2006 Aug 20;24(24):3946-52. (PMID: 16921047)
Cancer Treat Rev. 2016 Jan;42:10-7. (PMID: 26620819)
Cancer Prev Res (Phila). 2016 Mar;9(3):234-44. (PMID: 26667450)
Cancer Cell. 2006 Sep;10(3):241-52. (PMID: 16959615)
Cancer Res. 2007 Apr 15;67(8):3853-61. (PMID: 17440100)
Pancreas. 2010 May;39(4):425-35. (PMID: 20418756)
Oncotarget. 2014 Oct 15;5(19):9227-38. (PMID: 25193861)
Bioinformatics. 2011 Jun 15;27(12):1691-2. (PMID: 21493652)
Mol Cancer Ther. 2015 Mar;14(3):788-98. (PMID: 25527634)
Toxicol Rep. 2014;1:309-318. (PMID: 25530945)
Nat Methods. 2015 Apr;12(4):357-60. (PMID: 25751142)
PLoS One. 2011;6(10):e26943. (PMID: 22066019)
Proc Natl Acad Sci U S A. 2015 Aug 11;112(32):E4410-7. (PMID: 26216984)
Nature. 2011 Jul 13;475(7355):231-4. (PMID: 21753854)
Mol Cells. 2015 Apr;38(4):327-35. (PMID: 25813625)
Nat Rev Clin Oncol. 2010 Mar;7(3):163-72. (PMID: 20101258)
Biochem Pharmacol. 2000 Sep 15;60(6):749-58. (PMID: 10930529)
J Biol Chem. 2013 Jul 19;288(29):21197-207. (PMID: 23740244)
Front Biosci. 2006 Jan 01;11:300-12. (PMID: 16146732)
Nature. 2015 Oct 22;526(7574):596. (PMID: 26375002)
Cell Death Dis. 2011 Apr 28;2:e152. (PMID: 21525939)
J Med Food. 2016 Jun;19(6):578-85. (PMID: 27119744)
معلومات مُعتمدة: P20 GM109024 United States GM NIGMS NIH HHS; P30 GM103332 United States GM NIGMS NIH HHS; R15 CA206067 United States CA NCI NIH HHS; U54 GM115458 United States GM NIGMS NIH HHS
فهرسة مساهمة: Keywords: RNA-Seq; apoptosis; cell cycle regulation; complementary and alternative therapy; reactive oxygen species
تواريخ الأحداث: Date Created: 20180315 Latest Revision: 20220330
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC5828188
DOI: 10.18632/oncotarget.23623
PMID: 29535819
قاعدة البيانات: MEDLINE
الوصف
تدمد:1949-2553
DOI:10.18632/oncotarget.23623